Enza

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology

Retrieved on: 
Wednesday, April 24, 2024
Prostate, Enza, CD46, Prostate cancer, ASCO, Patient, Society, Annual general meeting, SAN

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.

Key Points: 
  • SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.
  • Details for the poster presentation are as follows:
    Session: Poster Session – Genitourinary Cancer – Prostate, Testicular, and Penile
    Title: A Phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).

The Miraculous Ecological Tale of Henan

Retrieved on: 
Wednesday, December 20, 2023
Multimedia, Government, Science and Technology Daily, International, Duck, Heart, Wetland, Plant, Exhibition, Enza, Volunteering, Poverty, Sewage, Hunting

Henan's commitment to a greener urban environment can be seen from its multiple initiatives that combine environmental protection with economic benefits.

Key Points: 
  • Henan's commitment to a greener urban environment can be seen from its multiple initiatives that combine environmental protection with economic benefits.
  • The ecological protection drives in this inland central province in the Yellow River valley are tackling alleviating extreme climate conditions and poverty in its suburban cities while building up foundations for their economic growth.
  • The Zhengzhou Longhu Park at the heart of Zhengzhou is a striking example.
  • The size of nearly two dozen soccer fields, it is the largest artificial wetland in Zhengzhou with natural water ecosystem protection and restoration functions.

Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Pharmaceutical, Health, Oncology, Docetaxel, Thyroid, Observational study, Mutation, ADT, Radium, Science, ASCO, DEAR, American Society of Clinical Oncology, Metastasis, Patient, NTRK, Annual general meeting, Disease, Copanlisib, RWE, Radium-223, FDA, Aryl hydrocarbon receptor, Safety, Society, ORR, TC, Enza, TRK, Medical imaging, Pharmaceutical industry, Daro District, Bayer

Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from June 2-6, 2023.

Key Points: 
  • Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from June 2-6, 2023.
  • These presentations continue to underscore the company’s commitment to drive treatment approaches through science and innovation in the oncology space.
  • Data featuring NUBEQA® (darolutamide) and Xofigo® (radium Ra 223 dichloride) will be showcased at ASCO.
  • NUBEQA data includes results from the DEAR trial, a retrospective, observational study evaluating real-world evidence (RWE) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Camber Spine Continues to Add to Its “All Angles” Product Portfolio with Latest Patent Approval

Retrieved on: 
Wednesday, April 27, 2022
Science, Other Science, Research, Surgery, Health, Medical Devices, Education, Training, Surgeon, AANS, CEO, United States Patent and Trademark Office, MIS, USPTO, Patent, Association, Patient, Pennsylvania Convention Center, Variant, Spine, IP, Collection, Anatomy, American Association of Neurological Surgeons, American Association, Spira, PLIF, Engineering, Congress of Neurological Surgeons, Pharmaceutical industry, Bookbinding, Enza

The Variant Retractor is a tool designed to provide flexible spacing support for a variety of spine surgical approaches.

Key Points: 
  • The Variant Retractor is a tool designed to provide flexible spacing support for a variety of spine surgical approaches.
  • As our IP portfolio continues to grow, so too does the positive impact we can make for our surgeon customers and their patients, said Camber Co-Founder and CEO, Daniel Pontecorvo.
  • Innovative spine and medical technology company Camber Spine Technologies is dedicated to creating surgeon-designed solutions in MIS and minimally disruptive access for the treatment of complex spinal pathology.
  • Incorporating state-of-the-art manufacturing, 3-D printing, and an acute sensitivity to patient anatomy, Camber Spine is making quantum leaps in the spinal fusion market.

Camber Spine to Roll Out Education Initiatives and Expand Product Portfolio in 2022

Retrieved on: 
Tuesday, February 22, 2022
Research, Medical Devices, Surgery, Biotechnology, Continuing, Training, Health, Science, Education, Other Science, AANS, NASS, Calendar, Elective surgery, Education, PLIF, Spira, Anatomy, AAOS, Surgeon, Spine, MIS, Oblique, Faculty, Program, Pharmaceutical industry, Enza

Camber Spine , a leading innovator in spine and medical technologies, has announced a robust calendar of clinical education and product portfolio expansions in 2022.

Key Points: 
  • Camber Spine , a leading innovator in spine and medical technologies, has announced a robust calendar of clinical education and product portfolio expansions in 2022.
  • Cambers plans for the year include four spine surgical training labs focused on the Oblique Lateral Interbody Fusion Surgery (OLIF) technique.
  • The labs, part of the Camber Education Program, are designed to give surgeons an opportunity to further their experience accessing the anterior spine (L2-S1) through an oblique approach.
  • Incorporating state-of-the-art manufacturing, 3-D printing, and an acute sensitivity to patient anatomy, Camber Spine is making quantum leaps in the spinal fusion market.